{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:08:56Z","timestamp":1790104136794,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.073","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T02:20:19Z","timestamp":1314066019000},"page":"7920-7924","source":"Crossref","is-referenced-by-count":9,"title":["Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults"],"prefix":"10.1016","volume":"29","author":[{"given":"Alan","family":"Leeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Carcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Effler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.08.073_bib0005","unstructured":"Jim Bishop. Letter from the Chief Medical Officer, 30 July 2010. Available from http:\/\/www.healthemergency.gov.au\/internet\/healthemergency\/publishing.nsf\/content\/012B6C32F2D2B4A1CA25763C001A6F73\/$File\/CMO-letter-30July2010.pdf [cited 5 January 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0010","unstructured":"World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season. WHO; Revised 8 Oct 2009. Available from http:\/\/www.who.int\/csr\/disease\/influenza\/200909_Recommendation.pdf [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0015","doi-asserted-by":"crossref","unstructured":"Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS. Severe febrile reactions to a 2010 trivalent inactivated influenza vaccine in young children in Western Australia. BMJ Open 2011. Available from http:\/\/bmjopen.bmj.com\/content\/early\/2011\/05\/28\/bmjopen-2010-000016.full.pdf [cited 25 July 2011].","DOI":"10.1136\/bmjopen-2010-000016"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0020","unstructured":"Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination: status report as at 2 July 2010. Updated 24 September 2010. Available from http:\/\/www.tga.gov.au\/pdf\/alerts-medicine-seasonal-flu-100702.pdf [cited 22 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0025","unstructured":"The Australian Immunisation Handbook, 9th ed. Available from http:\/\/www.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/Handbook-home [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0030","unstructured":"Greenberg M, Van Dinther K, Maraskovsky E. Adverse Events In Children Associated with 2010 Southern Hemisphere Seasonal Influenza Vaccine. 45th National Immunization Conference. March 28\u201331, 2011. Washington, DC. Abstract 25435. Available from http:\/\/cdc.confex.com\/cdc\/nic2011\/webprogram\/Paper25435.html [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0035","unstructured":"Therapeutic Goods Administration. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children, dated 8 October 2010. Available from http:\/\/www.tga.gov.au\/alerts\/medicines\/vaccine-overview.htm [cited 25 July 2011]."},{"issue":"July (32)","key":"10.1016\/j.vaccine.2011.08.073_bib0040","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.vaccine.2011.05.054","article-title":"Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms","volume":"29","author":"Blyth","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0045","unstructured":"Fluvax\u00ae vaccine 2010 (AUST R 91583) Product Information, May 2010, CSL Biotherapies, Victoria, Australia. Available from http:\/\/fluvax.healthwatch.com.au\/site\/Fluvax2010.pdf [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0050","unstructured":"Salisbury DM. Risk of febrile convulsions in children aged under five years and seasonal influenza vaccines marketed by Pfizer Vaccines (Enzira\u00ae and CSL Biotherapies generic influenza vaccine) Dear colleague letter dated 28 July 2010. Available from http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Dearcolleagueletters\/DH_117984 [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0055","unstructured":"Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Use of CSL Seasonal Influenza Vaccine (Afluria) in the United States During 2010\u201311. Morbidity and Mortality Weekly Report (MMWR) August 13, 2010\/59(31);989\u2013992. Available from http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5931a4.htm [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0060","unstructured":"Food and Drug Administration. Biologics License Application for Afluria manufactured by CSL, Limited. Number: 125254, September 19, 2007. Available from http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm127190.pdf [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0065","unstructured":"CSL AFLURIA\u00ae, Influenza Virus Vaccine, 2010\u20132011 Formula Influenza Virus Vaccine STN BL 125254\/181. Available at: http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm220730.pdf."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0070","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0264-410X(98)00467-8","article-title":"and the Italian SVEVA group. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study","volume":"17","author":"Spila-Alegiani","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0075","unstructured":"Summary of Adverse Event Following Immunisation Reports, Department of Health, Western Australia, 2010. Available from http:\/\/www.public.health.wa.gov.au\/cproot\/3684\/2\/Dale%20-%20Western%20Australia%20Adverse%20Events%20Following%20Immunisation%20Report_final_20110228_PA%20-%2016%20March%202011.pdf [cited 25 July 2011]."},{"issue":"December (3)","key":"10.1016\/j.vaccine.2011.08.073_bib0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1017\/S0022172400024414","article-title":"A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group","volume":"75","author":"Potter","year":"1975","journal-title":"J Hyg (Lond)"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2011.08.073_bib0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/infdis\/136.5.623","article-title":"A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children","volume":"136","author":"Gross","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0090","doi-asserted-by":"crossref","unstructured":"Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A\/Victoria\/75-A\/New Jersey\/76 and monovalent B\/Hong Kong\/72 influenza vaccines. J Infect Dis. 1977 Dec;136 Suppl:S507-17.","DOI":"10.1093\/infdis\/136.Supplement_3.S507"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2011.08.073_bib0095","first-page":"213","article-title":"Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel","volume":"145","author":"al-Mazrou","year":"1991","journal-title":"CMAJ"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2011.08.073_bib0100","first-page":"127","article-title":"Evaluation of adverse events after influenza vaccination in hospital personnel","volume":"142","author":"Scheifele","year":"1990","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0105","series-title":"International Symposium on Influenza Vaccines for Men and Horses, London 1972; Symp. Series Immunobiol. Standard, vol. 20","first-page":"92","article-title":"Deoxycholate-split influenza vaccines in infants and young children","author":"Warburton","year":"1973"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0110","unstructured":"Letter to CSL Biotherapies from Mary Malarkey, Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, Food and Drug Administration dated June 15, 2011. Available from http:\/\/www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/ucm259888.htm [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0115","unstructured":"World Health Organization. Weekly Epidemiological Record. 24 January 2003 No. 4, 2003, 78, 17\u201324. Available from http:\/\/www.who.int\/wer\/2003\/en\/wer7804.pdf [cited 25 July 2011]."},{"issue":"March (6)","key":"10.1016\/j.vaccine.2011.08.073_bib0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/367667","article-title":"Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?","volume":"36","author":"Skowronski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.073_bib0125","unstructured":"Influvac\u00ae-PI-AUST-1Dec 2009 M Solvay Pharmaceuticals, NSW, Australia. Available from http:\/\/calastica.com\/pdf\/fluvax\/2010\/influvac.PI.pdf [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0130","unstructured":"Australian Government, National Health and Medical Research Council, c2004, General guidelines for medical practitioners on providing information to patients. Available from http:\/\/www.nhmrc.gov.au\/_files_nhmrc\/file\/publications\/synopses\/e57.pdf [cited 25 July 2011]."},{"key":"10.1016\/j.vaccine.2011.08.073_bib0135","unstructured":"CSL Afluria Influenza Virus Vaccine Package Insert. STN BL 125254\/181. Table 5: Proportion of Subjects with Solicited Fever within 7 days of Vaccination with AFLURIA or U.S. Licensed Comparator Vaccine. Available from http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm220730.pdf [cited 25 July 2011]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11013326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11013326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T03:38:16Z","timestamp":1560483496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11013326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":27,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11013326"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}